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2 I.  INTRODUCTION 
1  In its Communication of 24 November 1993  on the framework for action in 
the field of  public health
1 the Commission defined objectives for protection of 
health as  laid  down in Article  3(o) and  129 of the  Treaty establishing  the 
European  Community.  The  role  of  the  Community  is  identified  as 
tn1derpinning  the  efforts  of the  Member  States  in  the  public  health  field, 
assisting in the formulation and implementation of objectives and strategies, 
and contributing to the provision of health protection across the Community, 
setting as a target the best results already obtained in a given area anytvhere in 
the Community. 
2  In initiating action Wlder Article 129, the Community has to address itself to 
preventing  diseases,· particularly the  'major  health  scourges'  and  protecting 
health.  Based upon criteria laid down in the Commission communication. rare 
diseases have been identified as a priority for Commtmity action. 
3  Public  health  is  by definition  addressed  to  the  health  needs  of the  entire 
population.  This  means  that  available  health  services  and  resources, 
particularly preventive measures, should be used for the benefit of as  many 
people as possible.  This principle applies just as much to those affected by 
rare  diseases  as  it  does  to  those  affected  by the  'major  health  scourges' . 
. However,  the  very fact  of the rareness· of the  low-prevalence  diseases  and 
conditions  and the  consequent lack of information  about them  can lead  to 
many  affected  by these  conditions  not  receiving  the  health  resources  and 
services they need.  This is· because there may be  a particular shortage  of 
relevant· information and expertise and a lack of consensus about appropriate 
intervention for a specific rare disease. 
4  The  Commission's  framework  communication  on  public  health  presents 
several criteria for deciding on Community priorities.  These are:  a disease's 
impact on morbidity and mortality, a disease's socio-economic impact, how far 
a  disease  is  amenable  to  effective  preventive  action  and  of  particular 
importance, how far there is scope for Community actions to complement and 
add value to what is being done by the Member States. 
5  Clearly rare diseases do not meet the criteria on a population level.  However 
at the level of the individual and family they do  cause significant premature 
morbidity, mortality or loss of  disability-free life.  With regard to whether they 
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3 are preventable, this varies between the thousands of rare diseases; some are 
now so,  some may become so in the future.  But the  final  criterion,  that  of 
providing added value at Community level has a particular relevance to  rare 
diseases. 
6  It is self-evident that rare or low-prevalence diseases have a limited impact on 
society  as  a whole  and  are  responsible  for  relatively  little  morbidity  and 
mortality.  They  cannot  therefore  be  considered  as  being  major  health 
scourges.  However,  they  are  by  no  means  unimportant  economically,  for 
providing  effective  advice,  diagnosis  and  health inteiVentions  tends  to  cost 
disproportionately more than simibir provision for more common conditions. 
7  In this area there is much that the Community can offer.  Work at Community 
level can confer a number of  important benefits.  In particular, because of the 
much larger population of the Community as' a whole, individual cases can be 
aggregated to fonn a much larger group sharing the same characteristics.  This 
provides the opportunity to undertake a much wider range of  inteiVentions and 
to initiate co-ordinated actions with patients who might otherwise be isolated 
or incorrectly diagnosed. 
8  The  public  health  importance  of rare  diseases  can  also  be  considered  in 
another way.  They can sometimes occur with greater frequency in particular 
regions and in specific population groups, such as ethnic communities, than in 
the national population as a whole.  Thus the consequences at national level 
may be slight, but at regional or group level they may be very significant.  This 
is particularly true for genetic diseases.  · 
9  Moreover, one should not forget the wider issue of diseases which are rare in 
the European Community but common elsewhere in the world. We could use 
our expertise to provide assistance in the fight against tropical diseases which 
are  rare  in  our lands  but,  can  cause  huge  suffering  and  loss  of life  in  the 
developing world. 
1  0  In addition, some diseases with a low prevalence at present may in the future 
become major health scourges.  This is for instance possible if the disease is 
caused  by  an  unknown  agent  as  was  the  case  with  IDV  I  AIDS  or  more 
recently with Bovine  Spongifonn Encephalopathy/Creutzfeldt-Jacob Disease 
(BSEICJD).  A similar effect can be caused by a newly introduced medicinal 
product, thalidomide being an obvious example.  A co-ordinated Community 
approach -offers an effective way to tackle these potentially large-scale health 
problems. 
4 II  Some diseases and· especially commwricable diseases which were once very 
.  common,  such  as.  poliomyelitis,  have  become rare  in the  Community  as  a 
·result  of effective  preventive  measures,  notably  paediatric  vaccinations. 
However,  such  diseases  can  and  do  re-emerge if  for  example  population 
immunity falls.  In this connection the sudden appearance of cases of such a 
disease  in one  c01mtry  can  provide  an  early  warning  to  others  that  their 
vaccinations  or  other  preventive  measures .may  be  becoming  ineffective. 
Action at Community level can help individual Memh., States to  recognise 
such problems at an early stage and to co-ordinate their response. 
I2  The aetiology of many diseases,  and especially rare  diseases,  is  unknown. 
Preventive  measures  are  dependent  upon  this  basic  lmowledge.  The 
thousands of  rare diseases or conditions, their low prevalence and the limited 
means and budgets for scientific research to unravel their aetiologies, make it 
less  likely  that  swift  progress  in  their  treatment  and  cure  will be made. 
Therefore collaboration between the Member States and work at Community 
level  in  this  domain  can provide  added  value  to  the  actions  of individual 
Member States. 
13  The  limited resources  within health  systems  are  primarily,  and necessarily, 
directed  at  major  health  scourges,  thus  there  is  likely  to  be  only  limited 
attention given to low-prevalence diseases in individual Member States.  It 
falls  within the  scope  of the  Community's  public  health  policy  to  help  the 
Member States achieve the most efficient use of  resources in this respect.  In 
the  case  of these  conditions  there  may  be  real  economies  of scale  by 
combining limited national expertise and resources at Community level. 
I4  It is for these reasons that the Commission has decided to give rare diseases 
priority within the pub~c  health framework. 
5 II.  IMPORTANT ASPECI'S OF RARE DISEASES 
INFORMATION 
15  An Wlknown nwnber of  Europeans suffer from rare diseases.  Many of these 
low-prevalence  diseases  have  no  specific  patient  support  organisation  or 
agency dedicated to  res~arch, prevention, diagnosis or treatment.  Infonnation 
of all  kinds  for  patients  and  their  f;unilies,  physicians,  researchers,  health 
authorities and the general public is lacking or poorly disseminated. 
16  For rare diseases the sources of  appropriate detection, recognition and medical 
care  are  limited  or  even  non-existent.  Little  or  nothing  is  available  for 
effective prevention and treatment; little may be known to inform the patient 
and  his  family  about  the  future  course  of the  disease,  the  possibilities  of 
avoiding risks  and the creation of environments and life-styles conducive to 
health. 
17  The US National Commission on Orphan Diseases has Wldertaken a detailed 
study of the problems of  people in the USA with these rare conditions.  This 
foWld-that it took between 1 and 5 years for one third of them to  receive a 
proper  diagnosis,  and  15%  went  Wldiagnosed  for  six  or  more  years. 
Moreover, the costs of these conditions,  in monetary and hwnan tenns,  are 
enonnous.  Half the patients said their illnesses caused great financial hardship 
for themselves and their families; and that their diseases prevented them from 
working or attending school.  · 
PATffiNTSUPPORTGROUPS 
18  Patient help groups can play a key role in rare diseases.  A number of such 
groups  covering many rare  diseases  have  been created in  the  past  decades, 
sometimes  in  response  to  a feeling  that  the  statutory  authorities  were  not 
devoting  sufficient  attention  to  these  conditions.  Moreover,  there  is 
considerable collaboration between these groups at regional and national level 
and internationally, often related to the different groups of diseases.  There are 
also  several  international  umbrella  organisations,  such  as  the  Emopean 
Alliance  of Genetic  Support  Groups  (EAGS).  These  patient  and  parent 
organisations have a wealth of lmowledge based upon their own experience 
with a disease.  This is particularly valuable given the facts of  frequent delay in 
establishing a diagnosis,  the limited knowledge of health care providers, the 
lack of  medicinal products, and health insurance problems. 
6 CLUSTERS 
19  In  considering  rare,  low-prevalence  diseases  and  conditions  it  is  useful  to 
address the issue of  clusters.  These can be defined as an aggregation in time 
and place of  occurrences of a rare disease.  Another way to put it is that in a 
defined area d1.1I'ing a defined period, conspicuously more cases oceutred of  a 
rare disease than was predicted from tho 'base-line' or the expected number of 
this condition.  The need to deal effectively with clusters, (i.e.  identifying a 
real increase, determining causal factors, assessing  imwcations and assuaging 
public concern) is obvious: a specific local factor could have been the cause, 
or contnbuted to the cause, and this has to be identified. 
20  In dealing with clusters the actions taken should follow a particular order: first, 
identification of  a cltister by for exaDlple early warning systems; second, using 
monitoring  and  surveillance  systems  to  establish  a  comparison  with  the 
established baselines for the relevant diseases, (however for rare diseases this 
process may not be possible because the necessary epidemiological data may 
not exist.); third there is the need to allay public concern by communicating as 
accurately as possible the risks  involved.  Han~g  clusters  effectively  has 
great benefits for public health.  This is not merely because responding to a 
particular problem  quickly and adequately can help avoid any possibility of a 
specific cluster developing into a wider problem, but more generally because it 
helps  create public  confidence in the  ability  of the  authorities  to  safeguard 
health. 
CLASSIFICATION OF RARE DISEASES 
21  ·  Improper  classification  of low-prevalence  diseases  and  lack  of official 
recognition  pose  problems  in  the  recognition,  detection,  treatment  and 
prevention of  those diseases.  Diagnoses identified in the WHO's International 
Classification  of Diseases  (ICD  10)  are  grouped  into  23  major  categories 
based on organ systems; these categories are subdivided into 4  70 diagnosis-
related  groups.  In  some  instances,  there  is  little  emphasis  on  individual 
diseases in these groups. 
22  Moreover,  the  validity  and  the  usefulness  of these  classifications  for  low-
prevalence  diseases  is  limited.  There  are  many  instances  in  which  these 
diseases are not included in conventional classification systems,  such as  the 
ICD and the British Paediatric Association classification for birth defects.  In 
other instances, low-prevalence diseases are inappropriately or inadequately 
7 classified:  the ICD  classification number assigned to Marfan  syndrome,  for 
instance, is shared by more than 20'other conditions. 
23  The  terms  rare  diseases  or low-prevalence  diseases  relate  to  perhaps  more 
than 5,000 different conditions or illnesses.  There seems to be no  common 
denominator  to  define  the  entity of a rare  disease.  Some  are  based upon 
syndromes  (the  combination of associated  symptoms  or  defects),  or  single 
defects  or  non-associated  conditions.  Obviously,  priorities  have  to  be  set 
when actions at a Community level have to be initiated. 
· III.  DEFINITION OF RARE DISEASES 
PROBLEMS WITH A NUMERICAL DEFINITION 
24  It  might seem that a definition of rare or low-prevalence diseases based upon 
numbers  of cases  would be  straightforward.  However,  in the  case  of rare 
diseases these data either do not exist, or if  they do, the figures produced on 
· the basis of  routine data collections will be broad estimates which are likely to 
Wlderstate the true rate. 
25  Difficulties in establishing precise prevalence and incidence rates may arise for 
several reasons: differences in defining a disease; a lack of specific methods to 
monitor patients with these low-prevalence diseases;  low diagnostic accuracy, 
particularly for the less serious diseases; and finally,  di$tortion of infonnation 
between data collection and analysis. 
26  Well-known  diseases  may  be  classified  and  sub-classified  repeatedly.  For 
instance, cancers are often differentiated by pathologic chissifications so that a 
number would fit numerical criteria for rare cancers.  On the other hand, the 
classification of less-understood diseases is sometimes based upon symptoms 
which  in  fact  group  several  diseases  together.  In this  way  specific  low-
prevalence diseases may be subsumed within larger entities. 
8 DEFINITION BY FIXED NUMBER OR LIMIT 
2  7  One way to  overcome the problems inherent in using a fixed nwnber for the 
definition of rare diseases· is to  establish limits.  The  Commission services 
have  discussed this  question with national  experts.  Several possibilities  for 
fixing limits were discussed:  a mortality rate not exceeding a  given certain 
figure  in  a  certain  nwnber  of Community  cowttries,  or an  incidence  not 
exceeding a given certain value or a reported prevalence among Community 
inhabitants not exceeding a certain value.  Another possibility might be the 
criterion that the  condition is  not among the  100  most common causes  of 
morbidity and mortality in the European Commtmity. 
PROPOSED DEFINITION 
28  For the  purposes of this  programme rare  diseases  will  be  defined  as  life-
threatening  or  chronically  debilitating  diseases  which  are  of  such  low 
prevalence that special combined effortS are needed.  They are those diseases 
with a generally-accepted prevalence in the  total  Commtmity population of 
less than 5 per 10,000.  Moreover, the diseases to be specifically addressed by 
this programme will be those where special combined efforts are needed to 
ensure  that  there  is  no  significant  prenatal  and  premature  morbidity  or 
mortality,  great  loss  of quality  of life  or socio-economic  potential for  the 
individual. 
RELATED ISSUES 
29  In considering actions on rare diseases we need also to take accowtt of other 
related areas of Commtmity work, such as research and the development and 
marketing of orphan products, including phannaceuticals, which are  mainly 
indicated for rare diseases.  Given that rare diseases involve small munbers, 
there is a need to establish a population large enough for research purposes, 
such  as  clinical  trials.  The  Commtmity  can take  action  in  this  regard. 
Similarly  the  commercial  interest  for  the  industrial  sector  in  developing 
medicinal products for small numbers of  potential patients is limited.  There is 
therefore a need to  encourage investment within the context of Community 
indust:Iy  policy.  Actions  in these  areas  can complement well  work in the 
public health domain. 
30  Within the field of  orphan medicinal products, a considerable amowtt of  action 
has been taken at Commtmity level.  Recently, for example, the Commission 
has  supported  studies  examining  the  issue  with  a  view  to  fonnulating  a 
9 Community  policy.  An  expert  group  was  convened  in  February  1995 
consisting of Commission officials and experts from both Member States  and 
other countries to consider the findings of  the studies and arrive at conclusions. 
During  1995  further  consideration  was  given  to  this  issue,  and  a  Council 
Resolution  on  this  was  adopted' on  20  December  1995,  which  invited  the 
Commission to undertake further work, particularly on the development and 
marketing of  orphan products. 
IV.  OVERVIEW OF PUBLIC HEALtH ACTIONS IN THE 
MEMBER  STATESANDINTERNATIONALLY 
CONCERNING RARE DISEASES 
MEMBER STATES 
31  A number of Member States are pursuing work with regard to  infonnation, 
detection, recognition, intervention and prevention of particular rare diseases, 
including  support for  patient  and  parent groups.  For example  the  United 
Kingdom has established a programme on Creutzfeldt-Jakob disease; France 
has  set up  a centre  of infonnation on  genetic  diseases  and  has  some  well-
established  centres  for  monitoring  and  surveillance  of birth  defects;  and· 
Portugal has a special interest in and is undertaking actions on paramyloidosis. 
32  On the basis of  infonnation received from the Member States it would appear 
that only a few Member States, notably·France, Sweden and Italy, which lias 
set up  a European School for Rare Diseases, are attempting to  address rare 
diseases in a  systematic way. 
INTERNATIONAL ACTIONS 
33  The cmmtiy that is very much in the lead on this is the United States. In 1983 
an Orphan Drug act was enacted to speed up the development and marketing 
of orphan  products.  Also  in  1983  the  National  Organisation  for  Rare 
Disorders  was  set up;  this  brings  together and  assists  the  voluntary  bodies 
which support people with rare diseases.  A National Commission on Orphan 
Diseases was fonned in 1985 to review national policy in this area. It reported 
in 1989.  Its main recommendations were that there should be a central focal 
point to foster the development, research and marketing of orphan products. 
Furthennore an Office ofRare Diseases at the National Institutes of  Health has 
been establish~d. 
Within  the  context  of co-operation  with  third  cowttries  and  following  the 
recent Joint EU-US Action plan, the two parties have among others pledged to 
10 establish a task force  to develop and implement an effective  global warning 
system  and  response  networlc  for  communicable  diseases,  including  rare 
diseases,  while  co-operating  on  respective  programmes  on  health-related 
matters and in the research field. 
V.  OVERVIEW OF COMMUNITY ACTIONS RELEVANT TO 
RARE DISEASES 
COUNCIL 
34  In its Resolution  of 20  December  19952 the  Council  and  the  Ministers  for 
Health,  meeting  within  the  Council,  invited  the  Commission,  in  close  co-
operation with the competent authorities of the Member States to take stock of 
the knowledge and experience available in the Member States, the Community 
and international organisations and to look into the situation of  orphan drugs in 
Europe  in relation to rare diseases. 
EUROPEAN PARLIAMENT 
35  In its Resolution A4-0311/953 on the Medium-Term Social Action Programme 
1995-1997 the Parliament asked the Commission to present, under the proper 
procedures,  the  action  programme  for  rare  diseases  foreseen  in  the 
Commission's framework communication on public health. 
ECONOMIC AND SOCIAL COMMITTEE 
36 
2 
3 
In its wide-ranging Opinion of 6 July  1994  on the Commission's framework 
communication on public health it urged  the  Commission to  adopt  a broad 
approach to the subject and emphasised the importance of  rare diseases. 
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11 VI.  COMMUNITY ACTION PLAN 
EUROPEAN COMMUNITY INFORMATION ON RARE DISEASES 
3  7  Accwate  information is  essential for  ensuring effective interventions  in  rare 
diseases.  The most immediate need of anyone with a rare disease is for  an 
accwate  diagnosis,  followed  closely by the  need for  treatment  and  support 
services.  Once diagnosed, patients ap.d their families are anxious to find  out 
all there is to know about their disease and often become experts on it.  They 
want information about the cause, prognosis, genetic basis (if  any), and future 
manifestations  of  the  disease,  the  availability  of  effective  therapeutic 
interventions  or,  if  none  exists,  how  to  cope  with  the  disease,  as  well  as 
information oil current research.  Patients want also information about support 
groups and treatment or focal centres. 
3  8  All these kinds of information, where they exist at all, are widely dispersed. 
Moreover, available information may relate to· a disease in general or a group 
of people,  but  it  may  be  specific  to  an  individual,  which  will  necessitate 
appropriate safeguards for confidentiality.  A further problem is  that several. 
different  groups  apart from  those  directly  concerned in  an  individual  case 
have  a  need  for  information  at  various  levels  of detail.  These  include 
physicians and researchers, governmental agencies, patient support groups and 
the pharmaceutical industry. 
39  In the light of the major advances being made in genetics and of the current 
difficulties in obtaining up to date information on rare diseases, set out above, 
there  is  a  pressing  need  for  a  Community  information  database  on  rare 
diseases and for a system for gathering and disseminating data. 
40  In developing such a Community system, there must be close liaison with the 
Community's  telematics  programme.  This  might  help  define  the  technical 
requirements  for  the  database  and  system  and  determine  the  most  effective 
mechanisms for disseminating the information to the different interest groups 
and the relevant agencies in the Member States.  A telematic network linking 
those  working  in  the  field  would  also  provide  a  mechanism  for  the 
identification of relevant research  and researchers  and  for  the  exchange  of 
information. 
41  The objective of Community action could be to provide a better information 
about  rare  diseases  especially  for  patients,  health  professionals  and 
researchers. 
12 42  The actions to be taken to achieve this objective could include: 
encouragement and support for  the  establishment of a European rare 
diseases database, with entries listing the disease name, synonyms, a general 
description  of the  disorder,  symptoms,  causes,  diagnostic  tests  available, 
affected  population,  standard  treatments,  investigational  treatments  (when 
available) and a list of  resources that can be contacted for further information 
about the condition; 
promoting access to information and co-ordinating existing information 
systems  and  services  by  supporting  the  setting  up'  and  strengthening  of 
networks at local, regional, national and community level; and 
organising consensus meetings  among health professionals in order to 
improve the early detection, recognition, intervention  and  prevention  of rare 
diseases. 
PATIENT AND FAMILY SUPPORT GROUPS 
43  These  organisations have  a wide-ranging role.  They support the  collection, 
dissemination  and  exchange  of knowledge  and  experiences,  foster  public 
awareness and stimulate research and raise ethical.issues.  They also provide 
counselling for individuals and ensme that patients' interests are safeguarded, 
for  example  in  terms  of confidentially  and  informed  consent  to  clinical 
procedures.  There  is  a need to  promote  the  development  of these  patient 
support groups so that all areas of  the Community are properly covered and to 
encourage their co-operation at regional, national and European level.  There 
is also a need to establish one or more umbrella organisations at Community 
level which can undertake a clearinghouse, linking and support role.  There are 
already some organisations, such as the European Alliance of  Genetic Support 
Groups (EAGS), that might be able to develop their activities in this way. 
44  One of the objectives of Community action could be to establish, foster and 
strengthen voluntaiy organisations involved in  supporting people  directly  or 
indirectly  affected  by  rare  diseases,  such  as  various  neurodegenerative 
conditions. 
13 45  The actions to be taken to achieve this objective could include: 
promoting the establishment of groups of  those personS with the same 
rare conditions or those professionally involved in order to  disseminate their 
experience, to facilitate training and to co-ordinate their activities  at national 
and Community level; 
promoting the groups' collaboration and networking and the  setting  up 
and fostering of  umbrella bodies, focusing particularly on  efforts  to  encourage 
the continuity of  work and cross-national co-operation. 
HANDLING OF RARE DISEASES CLUSTERS 
46  Handling  clusters  of cases  effectively  involves  analysing,  assessing  and 
managing the problem and communicating clearly to the public.  Such action is 
both necessary and  difficult.  The  necessity is  clear since  any local  factor 
which might have been the ca~ve  or contnbuting agent has to be identified. 
But it is  also  difficult  because  there  are  many  reasons  for  a cluster to  be 
identified, and all posSibilities need to be considered and investigated before a 
particular causal association is proposed.  However, clusters occur only rarely 
in any particular region.  This means that there is little opportunity for those 
involved in an individual case to gain the necessmy experience. 
4  7  In this  situation there would be  Value  in  establishing within  the  Community 
'Rare  Disease  Cluster  Response  Teams',  involving  ~ose with  appropriate 
expertise which would be available to give assistance to the local authorities 
concerned.  The  experience  gained recently with  Creutzfeldt Jacob  disease 
indicates the need for such an approach enabling the best use to be made of 
scarce expertise in risk assessment and management. 
48  In the  case  of clusters  of rare  diseases  there  is  a need for  the  creation  of 
networks  of focal  points  for  particular  rare  diseases  or  groups  of related 
diseases, which would help in providing early warnings of  potential problems, 
co-ordinating the investigation of  clusters and provide relevant infonnation, for 
example on expected prevalence levels, to the response teams.  These focal 
points will need a high level of expertise in epidemiology and statistics, and 
the epidemiological infonnation that is  available on low-prevalence diseases 
from monitoring and surveillance programmes, both those at Cornrmmity level 
and those undertaken nationally and regionally. 
14 4  9  .  As mentioned above, epidemiological data for rare ·diseases are not cwrently 
.  comprehensive.  Such data depend on effective monitoring and surveillance 
·  programmes.  The majority of rare diseases are congenital disorders,  and in 
this  area  a ·monitoring  and  surveillance  programme  ~has  been  set  up: 
EUROCAT  (European  Registration  of Congenital  Anomalies).  This  is  a 
concerted action with mainly participants from the Member States who locally 
and sometimes regionally study a population and investigate the number, type 
and  possible  causes  of birth  defects  in order  to  pre~nt these  congenital 
malformations.  The  Commission  contributes  :financially  to  EUROCAT. 
Other birth defects monitoring programmes exist in the Member States,  and 
collaboration with these programmes and with programmes that monitor other 
(groups of  rare diseases) is necessary to pennit.an optimal use and analysis of 
the available data. 
SO  The objective of  Community action would be to ensure an efficient handling of 
the problem of  clusters, which is of  key importance for rare diseases. 
51  The actions to be taken to achieve this objective coul9 include: 
supporting  the  monitoring  (sentinel)  of.rare  diseases,  including  birth 
defects,  genetic  disorders  or  diseases  of different  organ  systems  and  the 
appropriate techniques for low-prevalence diseases,  in order to meet  on the 
one hand the demands of detection, treatment and research and on the other 
hand the demands of  relevant statistical monitoring ; 
promoting  the  creation  of  rare  diseases  response  teams  and  of 
specialised training courses for those investigating clusters ;  · 
establishing surveillance systems and detecting timely possible clusters; · 
and 
encouraging the  exchange  of expertise  in  the  evaluation,  assessment, 
communication  and  management  of  clusters  of rare  diseases  that  are 
associated with exogenic causes. 
ORPHAN PRODUCTS 
52  In the  context of the  Community's work  on the  control and  authorisation of 
phannaceutical products, a legislative proposal is being prepared which has the 
aim of providing a legal framework fol.' 'orphan medicinal products'.  This will 
cover the  foll~wing areas:  designation of orphan medicinal products; support 
of research; market access; and monitoring, including phannacovigilance. 
15 As part of this proposal, the  Commission intends to propose a definition  for 
such  products,  along  the  following  lines:  any  substance  or  combination  of 
substances presented as proprietary medicinal product which is: 
used for the treatment, prevention or diagnosis of a life~threatening or 
chronically debilitating disease in hwnan beings, 
where that disease ~dication affects not more than 5 per 10,000 people 
in the European Community, and 
where the commercial return is insufficient. 
16 EUROPEAN  COMMUNITY  RESEARCH  ON  RARE  DISEASES  AND 
ORPHAN PRODUCTS 
53  The  Fourth  Framework  Programme  (1994  - 1998)  for  Research  and 
Technological Development
4 namely the Biomedecine and Health programme 
(Biomed2), area 1 "Phannaceutical research" and area 4.6 "Research on rare 
diseases" covers the research activities on the development of orphan drugs 
and supports the basic and clinical research on rare diseases 
54  Under the area of  ''Rare Diseases" the research tasks include the definition of 
diagnostic criteria,  causes,  genetic  aspects, and methods  of prevention,  with 
emphasis  on  the  establishment  of European  epidemiological  observatories, 
infonnation networks, and registries of  patients with rare diseases in order to 
increase infonnation available on rare diseases. 
55  Under the area of  "Phannaceutical research" the aim is to support research on 
the treatment of  rare diseases, including methodologies for fast-track schemes 
in the development of orphan drugs and repositories of  available orphan drugs 
in Europe. 
VII.  CONSULTATION, ASSESSMENT AND REPORTS 
CONSULTATION 
56  The actions of  this programme will be implemented in close collaboration with 
the Member States, particularly as regards co-ordination of their policies and 
programmes.  To facilitate this, the Commission proposes the  creation of an 
Advisory Committee of representatives of the Member States.  Appropriate 
links  will  also  be  maintained  with  the  WHO,  other  relevant  international 
organisations and third countries in accordance with the requirements  of the 
programme's actions. 
EVALUATION REPORTS 
57  Assessment of  the programme will be provided in two reports: 
a  mid-tenn  report  to  the  Council,  the  European  Parliament,  the 
Economic  and  Social Committee,  and the  Committee  of the  Regions.  The 
Decision 94/1110/EC of26  .. 04.1994, OJL126, 18.05.94, p.l, as amended by Decision 96/616/EC of 
25.03.1996, OJ L86, 04.04.96, p.69 
17 pmpose of the mid-term report is to ensure that the Community Institutions 
and, through them,  all the parties concerned, are kept fully informed  on the 
progress of  the actions undertaken.  It will include information on the projects 
supported under the different actions. 
a final  report  on  the  implementation  of the  programme,  which  will 
include  an  evaluation  of the  actions  undertaken,  will  be  submitted  to  the 
above-mentioned institutions by the  ~ommission after the  completion of the 
programme. 
GENERAL INFORMATION ACTIVITIES 
58  The Commission will ensure that reports on the activities undertaken are made 
available to concerned parties and the general public. 
59  Future Community public health action on rare diseases must take account of 
the existing large body of work, in particular that Wldertaken Wider Articles 
129 and  130f of  the EC Treaty.  In accordance with Article 129 of  the Treaty, 
the Community shall contribute towards ensuring a high level of  human health 
protection  by  encouraging  co-operation  between  Member  States,  lending 
support  to  their  actions  and  promoting,  in  close  contact  with  them,  co-
ordination of their policies and programmes,  and fostering co-operation with 
third  coWttries  and  international  organisatiens  competent  in  the  sphere  o_f 
public he.alth. 
18 Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DECISION 
adopting a programme of Community action 1999-2003 on rare diseases 
in the context of the framework for action in the field of public health 
\'1 1 
2 
3 
EXPLANATORY MEMORANDUM 
In its  Communication  COM(93)  559  final  of 24  November  1993  on  the 
framework for action in the field of  public health, the Commission outlined the 
principles  and strategy to  be followed  in undertaking Community  activities 
directed towards  the  attainment of the  objectives  on health protection laid 
down  in  Articles  3(o)  and  129  of the  Treaty  establishing  the  European 
Community. 
The role  of the  Community is  identified as  underpinning  the  efforts  of the 
Member  States  in the  public  health field,  assisting  in  the  formulation  and 
implementation of objectives and strategies, and contributing to the provision 
of  health protection across the Community, setting as the target the best results 
already obtained in a given area anywhere in the Community. 
In accordance with Article  129, the  Commission presents proposals for  the 
adoption by the European Parliament and the Council of incentive measures 
intended  to  contribute  towards  ensuring  a  high-level  of  human  health·  .  . 
protection. 
4  The aforementioned Commission communi<;ation sets out criteria on which to 
determine priority areas for Community. action  programmes.  In accordance 
with these criteria, rare diseases were identified as such a priority area. 
5  The  present  Commission  proposal,  based  on  Article  129  and  already 
announced in the Commission programme of  work for 1996, comes under the 
principle  of shared  competence  between the  Community  and  the  Member 
States, and seeks to improve information on rare diseases, support for patient 
groups  and risk analysis  and  risk management  in  case  of clusters  of rare 
diseases.  This Community action will follow the principles of  subsidiarity and 
proportionality. 
6  According to  the  principle  of subsidiarity,  action on matters  not under the 
exclusive competence of  the Community, such as action on rare diseases, must 
be tmdertaken by the Community only if  and in so far as, by reason of its scale 
or effects, it may be better achieved at Commmuty level. 
7  Rare diseases are those diseases with a generally-accepted prevalence in the 
total Community population of less than  5 per 10,000.  The  diseases  to  be 
20 specifically  addressed  by  this  programnie  will  be  those  where  special 
combined efforts aie needed to ensure that there is no significant prenatal and 
premature  morbidity  or mortality,  great  loss  of quality  of life  or  socio-
economic potential for the individual. 
8  The proposed 5-year action programme seeks to complement ongoing work in 
the Member States by actions addressed to the public, health professionals, 
and the authorities. 
9  With the limited resources available it would be impractical for a Community 
public health progranune to address all.the approximately 5,000 rare diseases 
and all aspects of  rare diseases. 
10  In selecting objectives and defining actions to be included in the programme, 
account has been taken of  the situation currently existing in the Member States 
and  at  Community  level  in  the  field  covered  by  the  progranune.  The 
progranune  aims  at bringing about  an accelerated  and effective  sharing  of 
infonnation, support for patient groups  and umbrella organisations,  and the 
efficient establishment of cluster response teams,  ~d  increased co-operation 
ofMember States.  This will avoid unnecessary duplication of  work and speed 
up the adoption of the best solution to problems common to all, the Member 
States concerning such diseases. 
11  Finally,  the  criterion  of providing  added  value  at  Community  level  has  a 
particular relevance to rare diseases, all of  the activities involved being of  such 
unique scale and effect as to provide added value to all Member States. 
12  This progranune  is undertaken on the basis of a European Parliament and 
Council  decision  pursuant  to  Article  129.  It does  not  come  under  the 
exclusive  competence  of  the  Community,  and  does  not  require  the 
harmonisation of  national provisions in the field covered. 
13  An evaluation of the  actions  implemented under the programme will  be 
provided in two reports: a mid-term report reviewing progress and a final 
report  on  the  implementation  of the  programme.  These  reports  will 
incorporate infonnation on Community financing in the various  fields  of 
action as well as the results of  evaluations.  They will be transmitted to the 
Council  and the  European  Parliam~nt, as  well  as  to  the  Economic  and 
Social Committee and the Committee of  the Regions. 
1\ Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DECISION 
adopting a programme of  Community action 1999-2003 on rare diseases 
in the context of the framework for action in the field of public health 
THE EUROPEAN PARLIAMENT AND THE COUNCll.. OF THE EUROPEAN 
UNION 
Having regard to the Treaty establishing the European Comrmmity, and in particular 
Article 129 thereof, 
Having regard to the proposal from the Commission, 
1 
Having regard to the opinion of  the Economic and Social Committee,
2 
Having regard to the opinion of  the Committee of  the Regions,  3 
Acting in accordance with the procedure referred to in Article 189b of  the Treaty, 
1.  Whereas,  the  very fact  of the  rareness  of the  low-pr~valence diseases .  and 
conditions and the  consequent lack of infonnation about them can lead to 
people  affected  by these  conditions  not receiving  the  health resources  and 
services they need; 
2.  Whereas, for the purposes of  this programme rare diseases will be defined as 
life-threatening  or  chronically  debilitating  diseases  which  are  of such  low 
prevalence that special combined efforts are needed to address  them~. 
3.  Whereas, in accordance with point (o) of Article 3 of the Treaty, Community 
action  shall include  contnbution towards  the  attainment of a high  level  of 
health protection; 
4.  Whereas Article  129  expressly provides for  Community competence in this 
field in so far as the Community contributes to it by encouraging co-operation 
2 
3 
11. 5. 
6. 
7. 
8. 
9. 
10. 
11. 
between the Member States and, if  necessary, lending support to their action; 
promoting co-ordination of their policies and programmes, and fostering co-
operation with third countries and international organisations competent in the 
sphere  of public  health;  whereas  Conummity  action  should  be  directed 
towards the prevention of  diseases, and the promotion of  health education and 
information; 
Whereas rare diseases have been identified as a priority area for Community 
action within the framework for action in the field of  public health
4
; 
Whereas in its Resolution (A4-0311/95) on the Medium-Tenn Social Action 
Programme  1995-1997
5  the  Parliament  asked  the  Commission  to  present, 
under the proper procedw-es, the action programme for rare diseases foreseen 
in the Commission's :framework communication on public health; 
Whereas, in accordance with the principle of subsidiarity, action on matters 
not under the exclusive competence of  the Community, such as action on  rare 
diseases, must be undertaken by the Community only if  and in so far as,  by 
reason of  its scale or effects, it may be better  achieved at Community level; 
Whereas, the Community can provide added value to the actions of Member 
States  concerning  rare  diseases.  through  the  co-ordination  of national 
measures,  the  dissemination  of information  and  experiences,  the  joint 
establishment of priorities, the development of networking as appropriate, 
selection of European Community-wide projects  and  the  motivation  and 
mobilisation of  all involved; 
Whereas  co-operation with the  international  organisations  competent in the 
field of  public health and with third countries should be fostered; 
Whereas,  by  providing  support  for  acquiring  .better  lmowledge  and 
understanding of, and wider dissemination of  infonnation about rare diseases 
and by developing actions complementary to existing Community programmes 
and  actions,  while  avoiding  unnecessary  duplication,  the  programme  will 
contribute to the achievement of the Community objectives set out in Article 
129; 
Whereas,  in  order to  increase  the  value  and  impact  o{  the  programme,  a · 
continuous assessment of the actions undertaken should be carried out, with 
COM (93) 559 final 
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1.3 particular regard to their effectiveness and the achievement of the objectives 
set and, with a view where appropriate, to making the necessary adjustments; 
12.  Whereas  this  programme  should be  of five-year  dwation in  order  to  allow 
sufficient time for actions to be implemented to achieve the objectives set; 
13.  Whereas  the  introduction of specific  Community  arrangements  will help  to 
ensure  that  all  Member  States  are  swiftly  informed  in  the  event  of  an 
emergency situation, so that the protection of  the population can be ensured; 
14.  Whereas  these  Community  arrangements  for  the'  rapid  exchange  of 
information  do  not  affect  the  Member  States'  rights  and  obligations  under 
Treaties or bilateral and multilateral conventions; 
15.  Whereas an agreement on a modus vivendi  between the European Parliament, 
the Council and the Commission concerning measures for the implementation 
of acts adopted under the procedure laid down in Article  189b of the  Treaty 
was reached on 20 December 1994. 
16.  Whereas  this  decision  lays  down,  a  financial  framework  constituting  the . 
principal point of reference, within the meaning of point 1 of the Declaration 
of  the European Parliament,  the  Council  and the  Commission of 6 March 
1995, for the budgetary authority during the annual budgetary procedure; 
1  7.  Whereas the Community's financial perspective is valid up until 1999 and 
will have to be revised for the period beyond that date; 
18.  Whereas  the  financial  framework  for  the  last  four  years  of the  programme 
(2000-2003) shall be detennined after the establishment of the future financial 
perspectives; HAVE DECIDED AS FOLLOWS: 
Article 1 
Establishment of the programme 
1.  A programme of  Commmrity action on rare diseases hereinafter referred to as 
"this  programme",  is  hereby adopted for  the  period  1 Janwuy  1999  to  31 
December 2003  in the  context of the  framework for  action in the  field  of 
public health. 
2.  The aim of this programme is to contribute towards ensuring a high level of 
health protection in relation to  rare  diseases  by providing knowledge  about 
these diseases by promoting and strengthening patient support groups and by 
fostering the setting up of  cluster response teams. 
3.  The  actions  to  be  implemented  Wlder  this  programme  and  their  specific 
objectives are set out in the Annex Wlder the headings: 
1)  Actions on Commmrity infonnation on rare diseaseS~ 
2)  Actions in support of  patient and family suppo~  groups 
3)  Actions on handling rare diseases clusters 
Article 2 
Implementation 
1.  The  Commission  shall  ensure  implementation,  in  close  co-operation  with  the 
Member States, of  the actions set out in the Annex. 
2.  The Commission shall  co-operate with institutions and organisations active in 
the field of  rare diseases. Article 3 
Budget 
1.  The fmancial framework for the implementation of the programme for  the 
year  1999. shall  be  ECU  1  ,3  Million,  in  keeping  with  current  financial 
perspectives. The  financial·· framework  for  the  final  four  years  of the 
programme  (2000-2003)  shall  be  detennined  in  detail  after  the 
establishment of  the future financial perspectives. 
2.  The annual appropriations shall be established by the Budgetary Authority in 
accordance with the financial perspectives. 
Article 4 
Consistency and complementarity 
The Commission shall  ~nsure that there is consistency and complementarity between 
the  Community  actions  to  be  implemented  under  this  programme  and  those 
implemented Wlder <?ther relevant Community prograriunes and actions. 
Article 5 
Committee 
1.  In implementing this action plan, the Commission shall be assisted by an advisory committee, 
hereinafter  referred  to  as  "the  Committee",  consisting  of two  representatives  from  each 
Member State, and chaired by  the Commission representative. 
'  The representative of  the Commission shall submit to the Committee a draft of · 
the measures to be taken concerning, in particular: 
~a)  the criteria, and procedures for selecting and financing projects 
under this programme; 
(b)  the evaluation procedure. 
TI1e Committee shall deliver its opinion on the draft, within a time limit which 
the  chairperson  may  lay  down  according  to  the  urgency  of the  matter,  if 
necessary by taking a vote. The opinion shall be recorded in the minutes; in addition, each Member State 
shall have the right to ask to have its position recorded in the minutes. 
The Commission shall take the utmost account of  the opinion delivered by the 
Committee.  It shall inform the Committee on the manner in which its opinion 
has been taken into account. 
The  representati-ve  of the  Commission  shall  keep  the  Committee  regularly 
inf01med  about  Commission  proposals  or  Community  initiatives  and  the 
implementation of  programmes in other policy areas which are relevant to the 
achievement of  the objectives of  this programme. 
Article 6 
International co-operation 
I.  In  the  course  of implementing  this  programme,  co-operation  with  third 
countries and with international  or~nisations competent in the field of public 
health shall be fostered. 
2.  This programme shall be open to participation by the associated countries of 
Central Europe  (CEC),  in  accordance  with the  conditions  laid  down  in  the 
Association  Agreements  or  Additional  Protocols  related  thereto  concerning 
participation in  Community programmes.  This  programme  shall  be  open  to 
participation by Cyprus and Malta on the basis of additional appropriations in 
accordance  with  the  same rules  as  those  applied  to  the EFT A countries,  in 
accordance with procedures to be agreed with those countries. 
Article 7 
Monitoring and evaluation 
I  In the  implementation of this  Decision,  the  Commission  sha1 l take 
the  necessary  measures  to  ensure  the  monitoring  and  continuous 
evaluation  of the  programme  taking  account  of the  general  and 
specific objectives referred to in Article 1 and in the Annex. 
1)-2  During  the  third  year  of this  programme,  the  Commission  shall 
present to the European Parliament and to the Council an evaluation 
report 
3  The Commission shall  submit to the European Parliament and the 
Council a final report on completion of  this programme. 
4  The Commission shall incorporate into these two reports infonnation 
on  Community  financing  in  the  various  fields  of action  and  on 
complementarity with the  other actions  referred to in Article 4,  as 
well·as the results of the evaluations. It shall also send them to  the 
Economic and Social Committee and the Committee of  the Regions. 
Done at Brussels, 
For the European Parliament 
The President 
For the Council 
The President. ANNEX 
SPECIFIC OBJECTIVES AND ACTIONS 
I.  ACTIONS ON COMMUNITY INFORMATION ON RARE 
DISEASES 
Objective:  to provide knowledge about rare diseases especially for patients, health 
professionals and researchers. 
1.  Encouragement and support for the establislunent of a European rare diseases 
database,  with  entries  listing  the  disease  name,  synonyms,  a  general 
description of the  disorder,  symptoms,  causes,  affected population,  standard 
treatments, investigational treatments (when available) and a list. of resources 
that can be contacted for further infonnation about the condition. 
2.  Promoting  access  to  infonnation  and  co-ordinating  existing  infonnation 
systems  and  services  by  supporting  the  setting  up  and  strengthening  of 
networks at local, regional, national and community level. 
3.  Organising consensus meetings among health professionals in order to improve 
the early detection, recognition, intervention and prevention of  rare diseases. 
II.  ACTIONS IN SUPPORT OF PATIENT AND FAMILY 
SUPPORT GROUPS 
Objective:  to  establish, foster and strengthen voluntaiy organisations involved  in 
supporting people directly or indirectly affected by rare diseases. 
4.  Promoting  the  establislunent  of groups  of  persons  with  the  same  rare 
conditions  or  those  professionally  involved  in  order  to  disseminate  their 
experience, to facilitate  training and· to co-ordinate their  ~ctivities at national 
and Community level. 5.  Promoting the  groups'  collaboration and networking  and  the  setting  up  and 
fostering of  umbrella bodies, focusing particularly on efforts to encourage the 
continuity of  work and cross-national co-operation. 
III.  AcriONS ON HANDLING RARE DISEASES CLUSTERS 
Objective:  to ensure an efficient handling of the problem of clusters, which is of 
key importance for rare diseases. 
6.  Supporting the monitoring (sentinel) of rare diseases, including birth defects, 
genetic disorders or diseases of different organ systems  and the  appropriate 
techniques for low-prevalence diseases, in order to meet on the one hand the 
demands  of detection,  treatment  and  research  and  on  the  other  hand  the 
demands of  relevant statistical monitoring. 
7.  Promoting  the  creation  of rare  diseases  response  teams  and  of specialised 
training courses for those investigating clusters. 
8.  Supporting SUIVeillance and early warning systems for clusters. 
9.  Encouraging  the  exchange  of expertise  in  the  evaluation,  assessment, 
communication and management of  clusters of  rare diseases that are associated 
with exogenic causes. FINANCIAL STATEMENT 
1  TITLE OF OPERATION 
Proposal for a European Parliament and Council Decision adopting a programme of 
Community action on rare ~s  in the context of  the framework for action in the 
field of  public health 
2  BUDGET HEADING INVOLVED 
B3-..... 
3  LEGAL BASIS 
Article 3(  o) and Article 129 of  the Treaty establishing the European Community. 
4  DESCRIPTION OF OPERATION 
4.1  General objective 
To contribute to achieving the objectives laid down by the Treaty: 
under Article 3 (  o  ), the Community is required to make a contribution to the 
attainment of  a high level of  health protection; 
-Article  129 requires  the  Community to  coiltnbute towards  ensuring a high-
level of  human health protection, in particular by encouraging co-operation between 
the Member States, and if  necessary lending support to their action, promoting co-
ordination of their policies and programmes,  and fostering  co-operation with  third 
countries and the competent international organisations in the sphere of  public health. 
Community action is directed towards the prevention of  diseases, in particular major 
health scourges,  by promoting research into their causes and their transmission,  as 
well as health information and education. 
The general objective of the action programme· is to contribute towards ensuring a 
high level of  health protection on rare diseases. 
The method for achieving this objective consists of  undertaking actions which: 
31 provide the opportwrity to undertake a much wider range of inteiVentions and 
to  initiate  co-ordinated  actions  with  patients  who  might  otherwise  be  isolated  or 
incorrectly diagnosed. 
provide infonnation on rare diseases 
strengthen the organisation and setting up of  patient and family support groups 
enforce the setting up of response teams involved in handling clusters of rare 
diseases. 
4.2  Period covered and arrangements for renewal or extension 
5 years: 01.01.1999 to 31.12.2003 
Report  on  implementation  to  be  transmitted  to  the  Council  and  European 
Parliament during the third year of  the programme 
Report  to  the  Council  and  European  Parliament  after  completion  of the 
programme together with the results ofe~uations. 
5  CLASSIFICATION OF EXPENDITURE OR REVENUE 
Non-compulsory expenditure 
Differentiated appropriations 
6  TYPE OF EXPENDITURE OR REVENUE 
Subsidy for joint financing with other sources in the public and/or private sector (not 
exceeding a certain percentage of  the total cost of  the proposed projects).  _ 
The level of  funding granted depends on the scope of the measure to be financed and 
on the  extent to which the  action programme is reflected in the  various  activities 
planned.  Such funding will not exceed 70% of the total budget eannarked for the 
proposed projects except in the case of  networks and work ordered and of direct use 
to the Commission, where the subsidy may amount to 100% . 
32 7  FINANCIAL IMPACf 
7.1  Method of  calculating the total cost of  operation (definition of  unit cost) 
The  method  of calculation  is  the  result  of experience  acquired  in  previous  activities  related  to 
environmental health. This encompasses the various types of  Community action listed in Table 4 
of Commission Communication COM(93) 559 final of  24 November 1993, and represents 10 
years of know-how in  financing  cooperative efforts with the Member  States and NGO' s of 
collection,  analysis  and  dissemination  of information,  setting  up  of networks,  survey  of the 
quality of  campaigns such as European weeks, establishment of  mechanisms and procedures of 
consultation and cooperation for setting common objectives and  for policy coordination and 
for the formulation and development of strategies at the Community level.  The specific cost 
estimates  are  based  on the  assumption  that  half of the  activities  to  be  undertaken  under  this 
programme will require 100 percent funding while the other half will require 50 percent funding and 
that the activities to be undertaken will involve most or all of the Member States.  An amount of 
ECU  1. 3 million is deemed necessary for the implementation of these activities for the year 
1999. The new budget framework for the final four years will be established in the year 2000 
taking into account the future Community's financial perspectives.  The annual allocations will 
be decided in accordance with the normal budgetary procedures. 
7.1.1  Data base about rare disease for patient$, health profess_ionnals and researchers 
.. 
Establishment of european rare diseases. data base,  with entries listing the disease name, 
synonyms,  a general  description  of the  disorder,  symptoms,  causes,  affected  population, 
standard treatments, investigational treatments (when available) and a list of  resources that 
can be contacted for further information about the condition.  The setting up  of this data 
base in 1999 is calculated as 600.000 Ecus. 
Organising consensus meetings on rare diseases  among health professionals in  1999 will 
cost 100.000 Ecus. 
7.1.2  Establishment ofvolontary organisations on rare diseues 
Meetings  in  order  to  promote  the  establishment  of volontary  organisations  involved  in 
supporting people affected by rare diseases in 1999: 200.000 Ecus. 
7.1,3  Efficient handling of clusters of rare diseases 
Setting up monitoring facilities of(sentinel) rare diseases will cost 300.000 Ecus in 1999. 
The creation of  rare diseases "response teams" and setting up training courses to investigate 
clusters will cost 100.000 Ecus in 1999. 7.2  Itemised breakdown of  cost (in ECU million) - indicative programming 
YEARS 
OB.JECfiVE  ACI10NAREA 
TOTAL 
1999  2000  2001  2002  2003 
To provide knowledge  Encouragement and support for the establishment  · 0.6 
about rare diseases  of  a European rare diseases database, with entries 
especially for patients,  listing the disease name, synonyms, a general  - - - - 0.6 
heatth professionals and  description of  the disorder, symptoms, causes, 
researchers  affected population, standard treatments,  . 
investigational treatments (when available) and a 
list of  resources that can be contacted for further 
information about the condition. 
Promoting access to information and co-ordinating 
existing information systems and services by 
supporting the setting up and strengthening of  - - - - - -
networks at local, regional, national and 
community level. 
Organising consensus meetings among health  0.1  I 
professionals in order to improve the early 
0.1  detection, recognition, intervention and prevention  - - - -
of  rare diseases. 
-~5 .. ~ 
YEARS 
OBJEt...IJVE  ACfiONAREA 
TOTAL 
1999  2000  2001  2002  2003 
To establish, foster and  Promoting the establishment of  groups of  those 
strengthen voluntary  persons with the same rare conditions or those  - - - organisations involved in  professionally involved in order to disseminate  - - -
supporting people  their experience, to facilitate training and to co-
directly and indirectly  ordinate their activities at national and Community 
affected by rare diseases.  level. 
Promoting the groups' collaboration and 
networking and the setting up and fostering of 
0.2  - - - - 0.2  umbrella bodies, focusing particularly on efforts to 
promote the continuity of  work and cross-national . 
co-operation.  . ·. 
36 YEARS 
OBJECTIVE  ACTION AREA 
TOTAL 
1999  2000·  2001  2002•  2003 
To ensure an efficient  Supporting the monitoring (sentinel) of  rare 
handling of  the problem  diseases, including birth defects, genetic disorders 
of  clusters, which is of  or diseases of  different organ systems and the  0.3  - - - - 0.3 
key importance for rare  appropriate techniques for low-prevalence diseases, 
diseases.  in order to meet on the one hand the demands of 
detection, treatment and research and on the other 
- hand the demands of  relevant statistical monitoring 
-
Promoting the creation of  rare diseases response 
teams and of  specialised training courses for those 
0.1  0.1  investigating clusters.  - - - -
Supporting surveillance and early warning systems 
for clusters. 
- - - - -
Encouraging the exchange of  expertise in the 
evaluation, assessment, communication and 
management of  clusters of  rare diseases that are  - - - - -
associated with exogenic causes. 
/ 
TOTAL 
1.3  p.m.  p.m .  p.m.  p.m.  1.3 
. 37 7.3  Indicative schedule of appropriations (in ECU million) 
TOTAL 
1999  2000  2001  2002  2003 
Commitment 
appropriations  1.3  - - - - 1.3 
Payment 
appropriations 
1999  0.78  0.78 
2000  0.52  - ·0.52 
2001  - - - -
2002  - - - -
2003  - - - -
Subsequent 
years  - - -
TOTAL 
1.3  p.m.  p.m.  p.m.  p.m.  1.3 
8  FRAUD PREVENTION MEASURES; RESULTS OF MEASURES 
TAKEN 
. 
The grant application fonns will require infonnation on the identity and nature of 
potential beneficiaries so that their reliability can be assessed in advance. 
38 Fraud  prevention  measures  (checks,  intermediate  reports,  final  report)  are 
included  in  the  agreements  or  contracts  between  the  Commission  and 
beneficiaries.  The Commission will check reports and ensure that work has been 
properly carried out before intermediate and final payments are made. 
In addition, spot checks are carried out by the Commission to verify how funds 
have  been used.  Checks have  already  been carried out  in other public  health 
budget lines in relation to the financial years 1991 to  1995 and have shown their 
effectiveness. 
9  ELEMENTS OF COST  -EFFECTIVENESS ANALYSiS 
9.1  Specific and quantifiable objectives 
The Community measures aim at contributing towards  ensuring a high level  of 
health protection on rare  diseases  by providing knowledge  about rare  diseases 
especially  for  patients,  health  professionals  and  researchers,  and  to  establish, 
foster  and  strengthen  voluntary  organisations  involved  in  supporting  people 
directly  and  indirectly  affected  by  rare  diseases,  and  by  ensuring  an  efficient 
handling of  the problem of  clu5ters, which is of  key importance for rare diseases : 
by the ac.complishment of  the following specific objectives: 
The indicators showing whether or not these objectives are achieved will include 
measures of  the following kinds:  · 
dissemination of  information on rare diseases to patients, health 
professionals and researchers;  . 
establishment of  a European rare diseases data base; 
availability of consensus documents about the detection, recognition, 
intervention and prevention of  rare diseases; 
presence and functioning of  local, regional, national and Community 
patient organisations active in the field of  rare diseases; 
presence of  umbr~lla  bodies at Community level for the promotion of 
collaboration on different rare diseases; 
existence of rare diseases response teams and of  specialised trading, 
surveillance, early warning systems related to clusters of rare diseases. 
Target Population 
39 1.  Competent health authorities of the Member States, at national,  regional 
and local level and competent international organisations in the sphere of 
public health; 
2.  Patient  support  groups,  health  professionals,  he8kh  and  medical 
associations, academic institutions etc.; 
3.  NGO's  and other bodies  interested in health matters,  and the  public  in 
general.  · 
9.2  Grounds for the operation 
In  initiating  action under Article  129,  the  Community has  to  address  itself to 
preventing diseases and protecting health.  The Commission's communication on 
the framework for action in the field for public health
1 sets out criteria on which 
to determine priority areas for Community progranimes.  In accordance with these 
criteria  the  framework  Communication  evaluated  the  different  options  for 
addressing diseases, in particular major scourges and their underlying causes, by 
various types of community actions and retained on the basis of criteria listed in 
that communication, eight priority areas of  which rare diseases was one. 
For the purposes of this programme rare diseases are defined as life-threatening 
or chronically debilitating diseases which are of such low prevalence that special 
combined efforts are needed as shoWn on the basis of  an ex-ante evaluation . 
The programme  aims  at bringing about an accelerated and effective sharing of 
infonnation and  experience,  Community wide understanding of key issues  and 
questions on tackling rare diseases, and increas~d co-operation of  Member States 
so as to avoid unnecessary duplication of  work and speed up the adoption of best 
solution to problems common to Member States concerning such diseases.  This 
input envisaged for the  Community and the  Commission by Article  129  of the 
Treaty provides a clear common framework of  rules: 
As  regards  the  intervention methods  and the  allocation of :funds,  the  following 
will apply: 
specific application of  the principle of  subsidiarity when identifying 
measures to be undertaken and co-financed; 
identification and sel~ction of  projects for co-financing in the fields of  rare 
diseases  · 
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40 the concept of  added Community value, which will continue to be realised 
in particular through the co-ordination of  national measures, the . 
dissemination of  information and experiences, the establishment of 
priorities, the development of  networking as appropriate, selection of 
European projects and the motivation and mobilisation of  all involved. 
Two methods will be employed to implement the programme.  One is to support 
projects canied out in Member States and at the Community level.  The selection 
of priority projects is based largely on general and intermediate objectives, and 
implementation  of  the  measures  themselves  depends  on  the  quality  and 
effectiveness of  projects submitted to the competent depart:Ment during the course 
of the year.  The other is to undertake specific activities necessa.cy to achieve the 
objectives of  the programme, which will be fully financed by the programme. 
The selection criteria for projects are as follows: 
Compatibility with the objectives and conformity with at least one of  the 
established objectives; 
Examination of  the "added Community value" of  the projects (transnational 
participation, development of  a model applicable in other Member States, 
information usable in other Member States, etc.); 
Presumed effectiveness and profitability; 
Clarity and justification of  requirements; 
Relevance of  selected methodology; 
Organisati~nal competence and experience; 
Suitability of  budget for objectives; 
Support for projects from national p~ers; 
Objective assessment; 
Opinion of  the advisory committee involved. 
The budget proposed of 1.3 MECU for the first year of this programme matches 
that proposed at the same time for the Community action programmes on injury 
prevention and pollution-related diseases. This reflects the equal priority attached 
to these fields  for action determined by the Commission communication on the 
framework for action in the field of public health (1993),  an evaluation which 
remains valid today. The amount proposed represents the bare minimum required 
to start the programme. 
9.3  Monitoring and evaluation of the operation 
tl 9. 3  .l Monitoring of  the operation 
Monitoring at the Community level is to be carried out by the Commission, which 
will submit a report half-way through the implementation of  the programme, and a 
final  report· after  its  completion  to  the  Council,  the  European  Parliament,  the 
Economic  and  Social Committee,  and  the  Committee  of the  Regions,  drawing 
from national reports as well as evaluations of the actions under the programme 
and of individuals projects. 
9.3 .2  Evaluation 
Evaluation will be by means of: 
An evaluation of  the main measures and of  subsidised projects involving, 
where necessary, the participation of  independent experts'; 
An evaluation report during the third year; 
An overall report on the quality and effectiveness of  projects implemented 
under the action plan, to be submitted by the Commission to the other 
Community institutions after completion of  the programme. 
Performance indicators selected for this evaluation: 
Evaluation of  projects by Commission officials and/or. those co-operating 
with them; 
Analysis of  intermediate reports on measures scheduled and fmanced, 
allowing a shifting of  emphasis where possible;  · 
Impact studies by external bodies 
Relevance of  the methodology used by organisers; 
Suitability of  the budget for the objectives; 
Skills and experience of  bodies; 
Dissemination of  results; 
Evaluation procedures and intervals: 
Drawing up of intermediate and final reports on the various measures 
undertaken in the field; 
Development of  a "standard" evaluation form for the measure, to be 
forwarded by the beneficiaries with their final reports, and checking of 
these documents by officials either at the Commission or in the field. 
1:2 10  ADMINISTRATIVE EXPENDITURE (PART A OF THE BUDGET) 
Actual  mobilisation  of the  necessary  administrative  resources  will  be  conditioned  by  the 
Commission's annual  decision on the allocation of resources,  having·· regard  in  particular to 
additional staff and funds provided by the budgetary authority. 
10.1  Imoast on the number of  employees 
• 
Types of  employees  staff carrying out action  source of  employee  duration 
permanent  temporary  from within DG  supplem 
employees  employees  or service  entary 
staff 
Officials or  A  1  0  1  0 
temporary  B  1  0  I  0 
agents  c  1 
1  0  1  0  . 
Other resources 
Total  3  0  3  0 
10.2  Financial impact of supplementary staff 
10.3  Increase in other running costs arising from the action 
Budget line  Amounts  Method of  calculation 
Meetings  104,250 ECU's  2 meetings of  advisory committee/year , · 
A2510  1 representative/Member State = 
2 ~eetings/year x 15 representatives x 695 
ECU/representatives  x 5 years= 104,250 
ECU's The resources necessary to cover the expenditure below for the 5-year period will be obtained by re-
deployment  of existing  financial  resources  and  the use  of supplementary  resources  will  not  be 
required. 
a)  Personnel Expenses (Title A1, A2 and AS) 
3 x 100,000 ECU's x 5 years= 1,500,000 ECU's 
b)  Operational Expenses 
c) 
Expenses for meetings (A-250)  . 
2 meetings/year x 15 experts x 825 ECU's/expert  x 5 years= 123,750 ECU's 
Expenses for travel (A-139) 
24 missions/year Brussels-Luxembourg x 200 ECU's/mission x 5 years= 
24,000 ECU's 
60 missions/year to Member States x 1000 ECU'  s/mission x 5 years = 
300,000 ECU's  .  . 
Total:  1,947,750 ECU's ISSN 0254-1475 
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